Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06908772 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients

Name: Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients — clinical trial record (NCT06908772)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2/3

SponsorShanghai JMT-Bio Inc.

Started2025-04-01

View on ClinicalTrials.gov ↗

Shanghai JMT-Bio Inc.

31 trials monitored

See all monitored trials

Non-Small Cell Lung Cancer (NSCLC)

2,914 trials monitored

See 156 trials at risk

To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.

Trial Details

NCT Number	NCT06908772
Lead Sponsor	Shanghai JMT-Bio Inc.
Conditions	Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression
Enrollment	390 participants
Start Date	2025-04-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2030-01-31 (estimated)
Updated on ClinicalTrials.gov	2025-04-03